Design Considerations for Optimizing Pharmacokinetic Profiles in Novel Conjugated Drugs
Time: 1:02 pm
day: Pre-Conference Workshop Day
Details:
Achieving a desirable efficacy and toxicity profile can be crucial for dose optimization, costeffectiveness and can ultimately determine whether a novel conjugate drug is worth investing in. This workshop will delve into how novel formats—such as peptide drug conjugates (PDCs) or bispecific ADCs, or novel payloads with different mechanism of actions, such as antibody degrader conjugates (AbDCs), or alternative linker or conjugation technology can improve the therapeutic outcomes of drug conjugates
Join this workshop to:
- Review case studies of recent clinical translation in conjugated drugs, discussing how pharmacokinetic (PK), pharmacodynamic (PD) endpoints can determine the key drivers of the efficacy and safety profiles of drug conjugates.
- Discuss the role and contribution of different components of drug conjugate (formats, linker-payload, and conjugation types) in overall stability and PK/PD attributes and targeted delivery of drug conjugates.
- Analyze the PK/PD, safety and efficacy endpoints across approved and advanced drug conjugates to gage the efficiency of the current ADC design in expanding the therapeutic window.
- Determine how novel formats, linker and conjugation technology, novel payloads and Drugto-Antibody Ration (DAR) can improve the efficiency of targeted delivery of next generation drug conjugates
